IASO Bio's Equecabtagene Autoleucel Gains First Approval Outside Mainland China

Macau approves IASO Bio's multiple myeloma therapy

IASO Bio Receives U.S. FDA Approval Of Investigational New Drug Application For Equecabtagene Autoleucel For Two New Autoimmune Disease Indications

IASO Bio Raises Nearly $75 Million in Series C1 Funding

Fierce Biotech | China's IASO nets $108M to advance cell therapies, antibodies for cancer, autoimmune disease

PRECISIOIN ONCOLOGY NEWS: In Brief This Week-IASO Biotherapeutics, Genentech, BioNTech

Trailing the Big Pharma players, a lesser known BCMA CAR-T candidate comes into the spotlight

Bristol Myers Squibb and bluebird cleared the first BCMA CAR-T therapy for multiple myeloma patients back in March, and J&J and their partners at Legend Biotech aren’t far behind. Now, a lesser known candidate developed in China is coming into the spotlight at EHA.